| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
(-)-Sparteine sulfate targets the cholinergic system, specifically inhibiting the release of acetylcholine. By reducing acetylcholine availability at the synapse, it modulates cholinergic neurotransmission. This mechanism underlies its anticonvulsant effects.
|
|---|---|
| ln Vitro |
In vitro, (-)-Sparteine sulfate inhibits acetylcholine release. Its activity is typically assessed in synaptosomal preparations or neuronal cultures by measuring the evoked release of acetylcholine. Its anticonvulsant effects are also studied in cellular models of neuronal excitability.
|
| ln Vivo |
In vivo, (-)-Sparteine sulfate has anticonvulsant effects. It is used in animal models of epilepsy to study its ability to suppress seizure activity. Its mechanism of action is related to its inhibition of acetylcholine release, which helps to dampen excessive neuronal firing.
|
| Enzyme Assay |
Non-cell-based assays for (-)-Sparteine sulfate can involve studying its interaction with targets involved in acetylcholine release. While it does not directly bind to a receptor, its effects can be studied using synaptosomal preparations. The compound's ability to inhibit [3H]-acetylcholine release can be measured in a cell-free system using isolated synaptic vesicles.
|
| Cell Assay |
For in vitro cellular assays, neuronal cultures or synaptosomal preparations are used. Cells are pre-loaded with [3H]-choline, which is converted to [3H]-acetylcholine. The evoked release of [3H]-acetylcholine is then measured in the presence or absence of (-)-Sparteine sulfate. The inhibition of release indicates its activity.
|
| Animal Protocol |
In vivo animal studies for (-)-Sparteine sulfate typically involve administering the compound to rodents (e.g., via intraperitoneal injection) in models of epilepsy, such as the maximal electroshock seizure (MES) test or the pentylenetetrazol (PTZ) seizure test. Its ability to reduce seizure severity or increase the seizure threshold is then assessed.
|
| ADME/Pharmacokinetics |
(-)-Sparteine sulfate has a molecular weight and formula as per its chemical structure (C15H28N2O4S). Its CAS number is 299-39-8. It is a naturally occurring alkaloid. It is typically supplied as a solid and should be stored according to the manufacturer's recommendations.
|
| Toxicity/Toxicokinetics |
The toxicity profile of (-)-Sparteine sulfate is not extensively detailed. As a plant alkaloid with pharmacological activity, it should be handled with caution. It is intended for research use only and not for human consumption. Standard safety precautions for handling alkaloids should be followed.
|
| References | |
| Additional Infomation |
A quinolone alkaloid isolated from various leguminous plants, including those in the genera Lupinus, Broom, and Broom. It has been used as an oxytocin and antiarrhythmic drug. Furthermore, it has attracted attention as a marker of the CYP2D6 genotype.
(-)-Sparteine sulfate (CAS#: 299-39-8) is a naturally occurring quinolizidine alkaloid with a defined mechanism of action as an inhibitor of acetylcholine release. It is used as a research tool to study cholinergic signaling and as an anticonvulsant in preclinical epilepsy models. |
| Molecular Formula |
C15H28N2O4S
|
|---|---|
| Molecular Weight |
332.46
|
| Exact Mass |
332.176
|
| CAS # |
299-39-8
|
| Related CAS # |
(+)-Sparteine;492-08-0;(-)-Sparteine;90-39-1
|
| PubChem CID |
23616742
|
| Appearance |
Typically exists as solid at room temperature
|
| Boiling Point |
340.9ºC at 760mmHg
|
| Melting Point |
135ºC
|
| Flash Point |
148.3ºC
|
| Vapour Pressure |
2.61E-11mmHg at 25°C
|
| LogP |
2.648
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
22
|
| Complexity |
344
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
[H][C@@]1(C2)[C@](CCCC3)([H])N3C[C@@]2([H])[C@@](CCCC4)([H])N4C1.O=S(O)(O)=O
|
| InChi Key |
FCEHFCFHANDXMB-UMEYXWOPSA-N
|
| InChi Code |
InChI=1S/C15H26N2.H2O4S/c1-3-7-16-11-13-9-12(14(16)5-1)10-17-8-4-2-6-15(13)17;1-5(2,3)4/h12-15H,1-11H2;(H2,1,2,3,4)/t12-,13-,14-,15+;/m0./s1
|
| Chemical Name |
(1S,2R,9S,10S)-7,15-diazatetracyclo[7.7.1.02,7.010,15]heptadecane;sulfuric acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0079 mL | 15.0394 mL | 30.0788 mL | |
| 5 mM | 0.6016 mL | 3.0079 mL | 6.0158 mL | |
| 10 mM | 0.3008 mL | 1.5039 mL | 3.0079 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
